Cathy Davies, Daniel Martins, Ottavia Dipasquale, Robert A McCutcheon, Andrea De Micheli, Valentina Ramella-Cravaro, Umberto Provenzani, Grazia Rutigliano, Marco Cappucciati, Dominic Oliver, Steve Williams, Fernando Zelaya, Paul Allen, Silvia Murguia, David Taylor, Sukhi Shergill, Paul Morrison, Philip McGuire, Yannis Paloyelis, Paolo Fusar-Poli
Abnormalities in functional brain networks (functional connectome) are increasingly implicated in people at Clinical High Risk for Psychosis (CHR-P). Intranasal oxytocin, a potential novel treatment for the CHR-P state, modulates network topology in healthy individuals. However, its connectomic effects in people at CHR-P remain unknown. Forty-seven men (30 CHR-P and 17 healthy controls) received acute challenges of both intranasal oxytocin 40 IU and placebo in two parallel randomised, double-blind, placebo-controlled cross-over studies which had similar but not identical designs...
January 19, 2024: Molecular Psychiatry